Oxygen-Independent Synchronized ROS Generation and Hypoxia Prodrug Activation with Z-Scheme Heterostructure Sonosensitizer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37856705.
- Also identified by DOI 10.1002/adma.202307929.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Combination therapy has emerged as a promising approach for effective tumor treatment. However, the combination of sonodynamic therapy (SDT) and hypoxia-activated prodrugs (HAPs) has not been explored due to the contradictory requirement of oxygen (O<sub>2</sub> ) for reactive oxygen species (ROS) generation and the necessity to avoid O<sub>2</sub> for the activation of HAPs. In this study, this challenge is addressed by developing BiOCl-Au-Ag<sub>2</sub> S Z-scheme heterostructure nanoparticles loaded with tirapazamine (TPZ) to achieve O<sub>2</sub> -independent therapy. These nanoparticles demonstrate efficient electron-hole separation under ultrasound irradiation while maintaining a high redox potential. The generated holes react with water to efficiently produce hydroxyl radicals, while the electrons autonomously activate TPZ, negating the need for O<sub>2</sub> . In vitro and in vivo assessments validate the effective tumor elimination by these Z-scheme nanoparticles without disrupting the hypoxic environment. This innovative design overcomes the limitations associated with O<sub>2</sub> requirement in SDT and introduces a novel strategy for HAP activation and synergistic therapy between ROS and HAPs-based therapy.
Medical subject headings
- Prodrugs
- Neoplasms
- Nanoparticles